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Summary 20 
Background 21 
Escherichia coli that produce extended-spectrum beta-lactamases (ESBLs) are an 22 
increasing cause of healthcare-associated infection and community healthcare facilities 23 
may be a reservoir for important epidemic clones.  24 
 Aim 25 
To retrospectively characterise and investigate the epidemiology of ESBL-producing E. 26 
coli collected in a Dublin hospital, during 2009 and 2010, and to investigate the 27 
dissemination of specific clones within hospital and community healthcare facilities.  28 
Methods 29 
Pulsed field gel electrophoresis (PFGE) was used to determine the genetic relatedness 30 
of 100 ESBL-producing E. coli isolates. Phylogenetic groups were determined and the 31 
O25b-ST131 clone identified in the collection. The genetic data was correlated with 32 
antimicrobial susceptibility, clinical and demographic data to explore the epidemiology of 33 
specific clones. 34 
Findings 35 
Phylogenetic groups B2 (62%) and D (18%) were the most common and were 36 
associated with non-urinary isolates (P<0.0001 by Fisher’s exact test).  Pulsed-field gel 37 
electrophoresis (PFGE) revealed twelve clusters (≥80 % similarity), the largest of which 38 
clustered with the epidemic UK strain A. Residents of long-term care facilities (LTCFs) 39 
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in the community exclusively carried the O25b-ST131 clone and phylogenetic groups 40 
B2 and D. 41 
Conclusion  42 
E. coli O25b-ST131 is largely responsible for ESBL-producing E. coli in LTCFs in 43 
Dublin. The distribution of ESBL-producing E. coli in our hospital and community 44 
highlights a ‘revolving door’ through which these resistant bacteria spread and 45 
disseminate. 46 
Key words: Extended-spectrum beta-lactamase, Escherichia coli, O25b-ST131 clone 47 
 48 
 49 
Introduction 50 
Since 2000, strains of Escherichia coli are the dominant extended-spectrum beta-51 
lactamase (ESBL) producers worldwide, with CTX-M-15 the most widely disseminated 52 
of the ESBL enzymes.1-2 According to the 2009 European Antibiotic Resistance 53 
Surveillance Network (EARS-Net) report, the prevalence of invasive E. coli resistant to 54 
third generation cephalosporins in Europe has increased  from 1.7% in 2002 to 8% in 55 
2009 (P<0.001) in 22 countries.3 ESBL-producers are increasingly prevalent in non-ICU 56 
settings which may be due to increased admission of patients with urinary tract or 57 
bloodstream infections from nursing homes and other community healthcare facilities.4-5 58 
Risk factors for infection with an ESBL-producer includes recurring urinary tract 59 
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infections (UTI) and underlying renal pathology, old age, nursing home residence and 60 
recent exposure to  β-lactams or fluoroquinolones.6  61 
Transmission of ESBL genes is facilitated by their frequent location on conjugative 62 
multiresistance plasmids and the association of these plasmids with local and epidemic 63 
clones of Enterobacteriaceae. The most notable of these is E. coli O25b-ST131, a 64 
fluoroquinolone-resistant strain of the B2 phylogenetic group, associated with the global 65 
dissemination of CTX-M-15.7-8 This pandemic clone comprises five closely related 66 
clusters in the United Kingdom (UK strains A-E), UK strain A is epidemic in the UK and 67 
is widespread among Irish hospitals and Belfast nursing homes.9-11 Nursing homes may 68 
be reservoirs of these clones in the Republic of Ireland. Similarly, the clinical 69 
characteristics of patients with ESBL-producing E. coli (ESBL-EC) in Ireland have not 70 
been extensively investigated. 71 
We characterised 100 ESBL-EC collected in a Dublin hospital, during 2009 and 2010, to 72 
determine their genetic relatedness and to investigate the dissemination of specific 73 
clones within hospital and community healthcare facilities. Clinical data, patient 74 
demographic data and antimicrobial susceptibility data relating to the isolates were 75 
analyzed to investigate the epidemiology of ESBL-EC. 76 
 77 
Materials and methods 78 
Study setting 79 
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Beaumont Hospital is a 700-bed tertiary referral hospital in Dublin, Ireland providing 80 
emergency and acute care to the local community of approximately 300 000 people. 81 
The microbiology laboratory receives specimens from the hospital and community 82 
healthcare facilities including general practitioners (GPs) and nursing homes.  83 
 84 
Bacterial strains 85 
The American Type Culture Collection (ATCC) strains E. coli ATCC 25922, E. coli 86 
ATCC 35218 and K. pneumoniae ATCC 700603 are ESBL-negative, ESBL-positive and 87 
blaSHV ESBL-producing controls respectively. Salmonella enterica serovar Braenderup 88 
H9812 was a molecular weight reference strain for PFGE. The National Collection of 89 
Type Cultures (NCTC) strain E. coli NC13441 (UK strain A) was a comparison strain for 90 
PFGE.12 One hundred ESBL-EC clinical isolates recovered from samples received by 91 
the diagnostic microbiology laboratory between January 2009 and December 2010 were 92 
studied. These were selected from all E. coli isolates (468) identified as ESBL-93 
producers within the time period and selection was based on prioritization of serious 94 
infections (e.g. bloodstream isolates) with an even temporal distribution of isolates. One 95 
representative isolate per patient was selected. Isolates were confirmed as ESBL-96 
producers phenotypically using Brilliance™ ESBL Agar (Oxoid Ltd., Cambridge, UK).  97 
 98 
Determination of the E. coli phylogenetic group and detection of E. coli O25b-99 
ST131 clone 100 
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E. coli clinical isolates and reference strains were assigned to phylogenetic groups A, 101 
B1, B2 or D using the triplex PCR method of Clermont et al.13 Strains not yielding PCR 102 
products were scored as unassigned.14 An allele-specific PCR of the pabB gene was 103 
used to identify clone O25b-ST131 among B2 phylogenetic group members as 104 
previously described.15  105 
 106 
Pulsed-field gel electrophoresis (PFGE) of E. coli clinical isolates 107 
Xba I-digested genomic DNA from E. coli isolates and UK strain A were subjected to 108 
PFGE according to the PulseNet standardized laboratory protocol for E. coli 16 109 
Electrophoresis was performed in a 1% (w/v) SeaKem agarose gel with 0.5 X Tris-110 
Borate-EDTA (TBE) buffer for 19h in a CHEF-DR III apparatus (Bio-Rad), (initial switch 111 
time 2.2 s, final switch time  54.2 s, 6 V, included angle of 120°, 14°C). Where DNA 112 
degradation occurred, electrophoresis was repeated with thiourea (50 µM) in the 113 
running buffer.17  Macrorestriction patterns were analysed using GelCompar II® 114 
software (Ver. 6.5, Applied Maths NV, Saint-Martens-Latem, Belgium). Variability was 115 
determined by the Dice coefficient using a tolerance of 1%. Strains were clustered 116 
according to the unweighted pair group average method. Clonal groups were assigned 117 
based on a similarity of ≥80% (≤6 band difference in restriction profile) as previously  118 
described.18 Isolates indistinguishable by PFGE were assigned the same alpha-119 
numerical PFGE type. 120 
 121 
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Antimicrobial susceptibility testing 122 
Antimicrobial susceptibility testing was carried out in the diagnostic microbiology 123 
laboratory of Beaumont Hospital using the BD Phoenix™ Automated Microbiology 124 
System and results were interpreted according to Clinical and Laboratory Standards 125 
Institute (CLSI) guidelines.19  126 
 127 
Data collection 128 
Patient demographic data, clinical data and antimicrobial susceptibility data for ESBL-129 
EC isolates were obtained by retrospective analysis of computerized hospital medical 130 
records. Clinical details, including patient outcome, were unavailable for community 131 
patients with ESBL-EC. 132 
 133 
Statistical analysis 134 
Numerical data were expressed as mean ± standard deviation (SD) or standard error of 135 
the mean (SEM) and inter-quartile range. Fisher’s exact test was used to compare 136 
categorical data. Tests were performed using Prism 4 for Windows and were two-tailed. 137 
 138 
Results 139 
Clinical features and patient demographics 140 
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Amongst 633 isolates identified as ESBL-producers during the study period 468 were E. 141 
coli, 57 were Klebsiella spp. and 18 were other Enterobacteriaceae (eg, Pseudomonas 142 
spp., Proteus spp., Morganella morganii). Patient demographic and clinical 143 
characteristics for 100 ESBL-EC isolates studied are outlined in Table ǀ.  Almost two 144 
thirds (65%) of patients were inpatients at the time of isolation of ESBL-EC. A further 22 145 
patient samples were from community healthcare facilities including nursing homes 146 
(NH; 9 %) and GPs (13%). Urinary isolates made up the majority of ESBL-EC (68%), 147 
with 38/68 (56%) from inpatients. Isolates cultured from blood (8), fluid (5), surgical 148 
theatre specimens (2), catheter/cannula tips (2) and nine of 12 respiratory isolates were 149 
from hospital inpatients. All GP and Emergency Department (ED) samples and 7/9 NH 150 
samples were urinary, with the remainder being wound swabs. Outpatient samples were 151 
urinary (4) and respiratory (3). Among inpatients, median length of stay (LOS) was 23d 152 
and in-hospital mortality was 20%. Two thirds of inpatients were on medical wards, the 153 
most common specialities being geriatric medicine (14%), respiratory medicine (11%), 154 
nephrology (9%), gastroenterology (8%) and rheumatology (8%). 155 
All isolates were multidrug-resistant (MDR) according to the definition of the European 156 
Centre for Disease Control and Prevention.20 Although all isolates were susceptible to 157 
meropenem, there was almost complete resistance to several beta-lactam 158 
antimicrobials including amoxicillin (100%), aztreonam (99%), cefuroxime (100%), 159 
cefazolin (100%), cefotaxime (97%), ceftazidime (99%) and cephalothin (100%). A 160 
relatively high resistance rate to other commonly used Gram-negative antimicrobials 161 
was evident, with the majority of isolates co-resistant to ciprofloxacin (73%), co-162 
trimoxazole (78%) and amoxicillin-clavulanic acid (72%). Overall, 64% of clinical 163 
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isolates showed reduced susceptibility to 3 or more non-β-lactam/combination 164 
antimicrobials. 165 
 166 
Genetic relatedness of isolates 167 
The relatedness of E. coli clinical isolates is represented in Figure 1. Phylogenetic 168 
groups were successfully assigned to 97% of E. coli clinical isolates. The most 169 
prevalent phylogenetic groups were B2 (62%) and D (18%). The other isolates 170 
comprised group A (10%) and group B1 (7%), most of which were recovered from urine 171 
samples (13/17; 76.5%). A significant association was found between group B2 and D 172 
isolates and non-urinary types with 26/32 isolates (81%) belonging to these groups 173 
versus four non-urinary isolates involving group A or B1 isolates (P<0.0001, Fisher’s 174 
exact test). Isolates responsible for bloodstream infections belonged to phylogenetic 175 
groups B2 or D. Of the 62 B2 phylogenetic group isolates, 54 (87%) belonged to the 176 
O25b-ST131 epidemic clone.  177 
PFGE analysis of 100 isolates revealed 87 distinct types of which 64 isolates were 178 
clonally related and comprised 12 clusters (A-L) based on a similarity of ≥80%. Cluster 179 
A was the largest group (n=34), all belonging to the O25b-ST131 epidemic clone and 180 
clustering with the epidemic UK strain A. Clusters B, C and D (n=5, 6 and 2 181 
respectively) also belonged to the O25b-ST131 clone but were <80% similar to UK 182 
strain A. Members of the remaining clusters also shared the same phylogenetic 183 
backgrounds, with clusters E, F and J belonging to group B2; clusters G, H and I 184 
belonging to group D and clusters K and L belonging to groups A and B1.  185 
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 186 
Epidemiology of clonal groups The epidemiological and antimicrobial resistance 187 
patterns of the clonal groups are summarised in Table ǀǀ. Cluster A isolates 188 
demonstrated distinctive resistance profiles to ciprofloxacin, trimethoprim, amoxicillin-189 
clavulanic acid and co-trimoxazole. Cluster G isolates displayed resistance to 190 
gentamicin, not evident in other clusters. The clusters with the most resistance to 191 
common Gram-negative antimicrobials were B2 phylogenetic group clusters J (resistant 192 
to 67% of six antimicrobials) and A (63%). Cluster L, containing group B1 isolates had 193 
the lowest proportion of co-resistances (25%). O25b-ST131 isolates comprised 21/27 194 
(78%) of piperacillin-tazobactam-resistant isolates and 10/11 (91%) of amikacin-195 
resistant isolates.  196 
All twenty patients that normally resided in LTCFs/NH in the community, eleven of which 197 
were hospitalised during the study period, carried clonal isolates. Seventeen were 198 
O25b-ST131 (including twelve cluster A isolates), and the remainder were phylogenetic 199 
groups B2 (1) and D (2).  Clonal ESBL-EC from clusters A (3), C (2) and I (1) were 200 
isolated from six of eleven hospitalised NH residents on the day of hospital admission. 201 
Members of six clonal groups were isolated from both NH residents and hospital 202 
inpatients during the study period (Table ǀǀ). Isolates belonging to cluster A were 203 
detected in residents of six long-term care facilities over 23 months and from 17 hospital 204 
wards. Cluster A isolates were also recovered from six different specimen sources and 205 
from all patient categories. The pandemic O25b-ST131 clone was less prevalent in 206 
patients that normally resided at home than in NH residents (37/80; 46% versus 17/20; 207 
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85%) P = 0.0022. Also all patients with sporadic ESBL-EC strains normally resided at 208 
home. The O25b-ST131 clone accounted for 33/65 (51%) of ESBL-EC recovered from 209 
hospital inpatients. Amongst GP urine samples 54% were positive for O25b-ST131 and 210 
belonged to clusters A(2), B(2) and D(1).   211 
 212 
 213 
Discussion 214 
This study reports a molecular investigation into ESBL-producing E. coli and their 215 
associated patient characteristics. E. coli accounted for 86% of ESBL-positive 216 
Enterobacteriaceae isolated during 2009 and 2010 in our hospital. Although 217 
bloodstream and respiratory isolates were prioritized to include those causing the most 218 
severe infections, the majority of isolates were of urinary origin, reflecting the increase 219 
in ESBL-producing E. coli UTI seen worldwide.6 Over two thirds of patients carrying 220 
ESBL-EC were over 65 years old and almost three quarters were resident in a 221 
healthcare facility at the time of sample collection, either in hospital (65%) or in a 222 
nursing home (9%). The median length of stay for inpatients was relatively high (23d) 223 
matching the median LOS found for patients in a recent study from a Belgian hospital of 224 
similar size.21 Extended hospital stay is a known risk factor for hospital-onset ESBL-225 
producer infection.6 226 
The majority of study isolates were non-susceptible to β-lactam antimicrobials but all 227 
were susceptible to meropenem. Frequent non-susceptibility to other antimicrobial 228 
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classes was observed with 64% of isolates non-susceptible to at least three of six non-229 
β-lactam or β-lactam-inhibitor combination antimicrobials. The high level of resistance to 230 
β-lactam-inhibitor combination antimicrobials amoxicillin-clavulanic acid and piperacillin-231 
tazobactam, suggests concomitant production of other beta-lactamase enzymes such 232 
as those belonging to Ambler classes A (e.g penicillins TEM-30 and SHV-10), C (e.g. 233 
AmpC) or D (OXA enzymes).22-23 The variability in antimicrobial resistance observed 234 
between isolates of the same clonal group may be explained by differences in the 235 
content and structure of mobile genetic elements, such as resistance plasmids and 236 
integrons.  237 
A previous Irish study of ESBL-producing Enterobacteriaceae isolates from 25 different 238 
laboratories over an 11 year period highlighted the high prevalence of resistance to 239 
ciprofloxacin and we found similar prevalence rates amongst E. coli (73 %).9 Resistance 240 
to gentamicin was less prevalent at 24% of ESBL-EC (24/100) compared to 38% 241 
(176/462) of ESBL-producing Enterobacteriaceae, 85% of which were E. coli. The 242 
continuing trend towards multidrug resistance that limits empirical therapy choices for 243 
Gram-negative infections is evident. Excluding meropenem, only amikacin and 244 
nitrofurantoin were effective antimicrobials in terms of in-vitro susceptibility (97% and 245 
90% of isolates).  246 
Most isolates belonged to the B2 (62%) and D (18%) phylogenetic groups which contain 247 
virulent extra-intestinal strains.24 In the present study, strains belonging to these groups 248 
were significantly associated with non-urinary isolates and all bloodstream isolates 249 
belonged to these groups. Phylogenetic groups A and B1, which are associated with 250 
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human and animal commensal strains, were represented by only 17 isolates, the 251 
majority being from urine samples (13/17, 76%). 252 
The pandemic O25b-ST131 clone was predominant in the collection, represented by 253 
over half of all isolates and the majority of B2 phylogenetic group isolates (87%). This 254 
virulent uropathogenic strain is described in all five continents and is commonly co-255 
resistant to fluoroquinolones.25 In our collection, O25b-ST131 clone members were 256 
represented by five clusters (A-D and J), the largest containing 34 isolates and 257 
clustering with epidemic UK strain A. The distinctive antimicrobial resistance profile of 258 
UK strain A was also observed in cluster A, i.e. resistance including ciprofloxacin and 259 
trimethoprim and marked susceptibility to gentamicin.12 The widespread dissemination 260 
of this strain is evidenced by its isolation from all patient categories.  261 
A nationwide study of 69 Irish LTCFs in June 2010 revealed a prevalence of healthcare 262 
associated infection (HCAI) of 3.7% among 4170 patients. Over one third (35.8%) of 263 
antibiotic prescriptions were intended for prophylaxis of UTI; however UTI remained the 264 
most common HCAI (40%). It is possible that the practice of prophylactic prescription for 265 
UTI may have contributed to the success of the MDR ESBL-EC strains in Irish LTCFs, 266 
especially the uropathogenic O25b-ST131 clone.26 In the present study all twenty 267 
patients normally residing in LTCFs  had clonal ESBL isolates belonging to phylogenetic 268 
groups B2 and D and 17/20 were O25b-ST131. This suggests that E. coli O25b-ST131 269 
and some other virulent clones may be largely responsible for ESBL-EC 270 
infections/carriage in LTCFs. In contrast patients with sporadic strains all normally 271 
resided in their home, which suggests that a greater variety of ESBL-EC strains 272 
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circulate in the community compared to LTCFs. However the high proportion of O25b-273 
ST131 amongst ESBL-EC positive inpatients (51%) and GP urine samples (54%) 274 
suggests this clone is dominant in hospital and community settings. 275 
Although difficult to identify definitive transmission events based on the recovery of 276 
indistinguishable PFGE types alone, we can speculate that ESBL-EC strains may have 277 
disseminated throughout the hospital and from LTCFs in the community to the hospital. 278 
For example, three isolates from cluster A2 (0026-0028) were isolated within three days 279 
of each other from patients on three geographically separate wards. Two of these 280 
patients originated from the same nursing home and an ESBL-EC was isolated from 281 
one of these patients upon hospitalization. The recovery of identical strains (F1 (0041 282 
and 0042) may indicate cross infection with the postulated route of spread from an ED 283 
patient to a surgery patient. However certain clonal strains including UK strain A may be 284 
endemic in the hospital and this may account for their recovery from multiple hospital 285 
patients over extended time periods. For example PFGE type A2 isolates were 286 
recovered from five geriatric patients, all from different hospital wards over 18 months. 287 
Although the origin of the strains is not clear, it is evident that both the hospital and 288 
LTCFs in the community are now a reservoir for many of the same ESBL-EC clones.  289 
There are limitations to the study.  Due to time and resource constraints consecutive 290 
isolates were not studied.  Therefore the isolate collection represents just over one fifth 291 
of ESBL-EC isolates recovered during the study period.  Bloodstream and respiratory 292 
isolates were prioritised and therefore are over-represented in this study. This may have 293 
introduced bias to certain clinical characteristics. Limited reliable data on previous 294 
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hospital contacts for this patient cohort precluded the definition of infections as 295 
healthcare-associated or community-associated.   296 
This study describes the epidemiology and molecular characteristics of ESBL-EC 297 
clones in an Irish hospital. Similar to the pattern observed in other European countries 298 
and world-wide, our study highlights the importance of the epidemic O25b-ST131 clone 299 
as the major category of ESBL-producing E. coli in our hospital and local community.25, 300 
27 The dissemination of clones throughout the hospital and between several LTCFs in 301 
the local community and the hospital is supported by the identification of highly similar 302 
or identical PFGE types among hospital and NH patients and the predominance of the 303 
O25b-ST131 clone in both settings. This indicates the potential for continuous 304 
recirculation of this clone between healthcare facilities.  This ‘revolving door’ mechanism 305 
for the spread of ESBL-EC in our catchment area highlights the challenges faced in 306 
preventing and controlling their spread. 307 
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Table ǀ. Demographic and clinical data of 100 patients with ESBL-producing E. coli.  405 
Characteristic 
 
 Value 
 
 
 
Patient demographics  
Male: female 37:63 
Mean age, y ±SD [SEM] (range) 67± 21[2](11-100)  
Residents of nursing homes or long term care facilities 20 
Patient types  
Hospital inpatients  65  
Emergency Department patients  6 
Outpatients  7 
GP referral patients  13  
Nursing home patients  9 
Length of stay^  
Mean LOS d ±SD(SEM) 97.5 ± 232(28.8) 
Range d 0.5-1434 
Inter-quartile range d 8-49 
Median LOS d 23 
Time from admission to collection of ESBL-EC ^  
Mean time d ±SD(SEM) 63.5 ± 178.5(22.3) 
<7d n(%) 32(49) 
≤30d n(%) 50(77)  
>30d n(%) 15(23)  
Clinical specimen type  
Blood  8 
Urine  68 
Respiratory  12 
Wound Swab  3 
Fluid  5  
Others  4 
Inpatient outcome^  
Discharged home n(%) 33(51) 
Discharged to nursing home n(%) 10(15)  
Transferred to other hospital n(%) 6(9)  
Deceased n(%) 13(20)  
Other n(%) 3(5)  
 
^ = Inpatients only (65/100 patients), LOS = length of stay 406 
21 
 
Table ǀǀ. Phenotypic and epidemiological characteristics of clonal groups. 407 
PFGE 
cluster   
(No. of 
isolates) 
Antimicrobial 
resistance
a 
Antimicrobial 
susceptibility
b 
Percentage 
of co-
resistance
c 
Patient categories         
(No. of isolates) 
d 
NH residents
e 
A (34) CIP TMP AMC 
SXT 
GEN  63 E(1) GP(2) I(23) O(2) 
NH(6) 
12 
B (5) CIP TZP AMK 43 GP(2) I(3) 1 
C (6) CIP AMK 42 I(4) O(1) NH(1) 3 
D (2) - TZP AMK 33 GP(1) I(1) 0 
E (2) TMP SXT CIP GEN AMK 33 E(1) NH(1) 1 
F (2) TMP AMC SXT CIP GEN AMK 
TZP 
33 E(1) I(1) 0 
G (3) GEN TMP SXT CIP  TZP AMK 39 I(3) 1 
H (2) - TZP AMK 33 I(1) O(1) 0 
I (2) TMP AMC SXT TZP AMK 50 I(2) 1 
J (2) TMP TZP AMC 
SXT 
GEN 67 I(1) NH(1) 1 
K (2) CIP SXT GEN AMK 50 I(1) O(1) 0 
L (2) - GEN TZP AMK 25 I(2) 0 
a = >90% of strains tested were resistant to the listed antibiotics.  408 
b = 100% of strains tested were susceptible  409 
a, b Antimicrobials: AMC; amoxicillin/clavulanate, AMK; amikacin, CIP; ciprofloxacin, 410 
GEN; gentamicin, SXT; trimethoprim/sulfamethoxazole, TZP; piperacillin/tazobactam, 411 
TMP; trimethoprim (urinary isolates only).  412 
c Percentage of total antimicrobial susceptibility tests to the 6 antimicrobials listed above 413 
(excluding trimethoprim) with resistant result.  414 
d E; emergency department patients, GP; GP patients, I; inpatients, O; outpatients, NH; 415 
nursing home/long term care facility patients. 416 
e Patients normally residing in nursing homes/long-term care facilities. 417 
 418 
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 419 
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Figure 1. Dendrogram showing PFGE profile types (A-L) and E. coli phylogenetic 420 
groups (PG). Pairwise cluster analysis was performed using the Dice coefficient with an 421 
optimisation of 1% and a band matching tolerance of 1%. Columns L to R: Isolate = 422 
clinical isolate number; Source = source of clinical specimen; Patient type: I = inpatient, 423 
O = outpatient, E = emergency department patient, NH = nursing home patient, GP = 424 
GP patient; PG = phylogenetic group; PFGE type: clusters A to L were identified based 425 
on a similarity of ≥80% with distinguishable members numbered consecutively. Isolates 426 
that were indistinguishable by PFGE were given the same PFGE type code; Date 427 
collected = date of first isolation of E. coli; Speciality = medical speciality, (S) denotes 428 
surgical; * = O25b-ST131 positive by PCR. 429 
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